CL2022003725A1 - Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6. - Google Patents

Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.

Info

Publication number
CL2022003725A1
CL2022003725A1 CL2022003725A CL2022003725A CL2022003725A1 CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1 CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1
Authority
CL
Chile
Prior art keywords
treatment
activity
diseases associated
aberrant
interleukin
Prior art date
Application number
CL2022003725A
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/ru
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of CL2022003725A1 publication Critical patent/CL2022003725A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2022003725A 2020-06-26 2022-12-22 Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6. CL2022003725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (ru) 2020-06-26 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Publications (1)

Publication Number Publication Date
CL2022003725A1 true CL2022003725A1 (es) 2023-05-19

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003725A CL2022003725A1 (es) 2020-06-26 2022-12-22 Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.

Country Status (7)

Country Link
CN (1) CN115803026A (fr)
BR (1) BR112022026356A2 (fr)
CL (1) CL2022003725A1 (fr)
CO (1) CO2023000604A2 (fr)
MA (1) MA58653B1 (fr)
TN (1) TN2022000350A1 (fr)
WO (1) WO2021262040A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (fr) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Utilisation de 1-(2-(1н-imidazol-4-yl)éthyl)pipéridine-2,6-dione pour le traitement de la toux induite par des infections virales
WO2023249516A1 (fr) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Nouvelle forme cristalline de 1-[2-(1-méthylimidazol-4-yl)éthyl]perhydroazine-2,6-dione et utilisation pharmaceutique de celle-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN102432544B (zh) * 2011-11-17 2014-05-21 天津医科大学 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
CN115867275A (zh) * 2020-04-13 2023-03-28 大学健康网络 治疗细胞因子释放综合征的方法
CN113582980B (zh) * 2020-04-30 2023-11-24 上海科技大学 基于杂环和戊二酰亚胺骨架的化合物及其应用

Also Published As

Publication number Publication date
MA58653A1 (fr) 2023-07-31
WO2021262040A1 (fr) 2021-12-30
CN115803026A (zh) 2023-03-14
MA58653B1 (fr) 2024-02-29
CO2023000604A2 (es) 2023-01-26
RU2020121363A (ru) 2021-12-27
RU2020121363A3 (fr) 2021-12-27
BR112022026356A2 (pt) 2023-01-17
TN2022000350A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2022003725A1 (es) Uso de un derivado de glutarimida para el tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6.
CO6460772A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2024003923A2 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
UY38144A (es) Inhibidores de la señalización mediada por tirosina cinasa
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
ECSP12011638A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
SA521430084B1 (ar) مركب حلقي غير متجانس، وتركيبة صيدلية تشتمل عليه، وطريقة لتحضيره واستخدامه
CO7380758A2 (es) Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno